机构持仓方面，截止2025年6月30日，招商南油十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股6413.52万股，相比上期减少7092.47万股。南方中证1000ETF（512100）位居第九大流通 股东，持股3588.07万股，相比上期增加680.34万股。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 资料显示，招商局南京油运股份有限公司位于江苏省南京市鼓楼区中山北路324号油运大厦，成立日期 1993年9月8日，上市日期2019年1月8日，公司主营业务涉及沿海和国际航线石油运输业务。主营业务收 入构成为：成品油运输57.92%，原油运28.82%，化学品运输7.20%，乙烯运输3.07%，船员租赁2.28%， 其他(补充)0.67%，船舶管理费及其他0.04%。 招商南油所属申万行业为：交通运输-航运港口-航运。所属概念板块包括：港口运输、低价、央企改 革、一带一路、增持回购等。 截至7月31日，招商南油股东户数14.77万，较上期减少10.37% ...

8月22日，阿拉丁盘中上涨2.08%，截至10:54，报15.67元/股，成交6911.93万元，换手率1.34%，总市值 52.12亿元。 资金流向方面，主力资金净流出457.08万元，特大单买入0.00元，占比0.00%，卖出244.22万元，占比 3.53%；大单买入1164.49万元，占比16.85%，卖出1377.35万元，占比19.93%。 资料显示，上海阿拉丁生化科技股份有限公司位于上海市浦东新区新金桥路36号南塔16楼，成立日期 2009年3月16日，上市日期2020年10月26日，公司主营业务涉及试剂的研发、生产及销售。主营业务收 入构成为：高端化学42.21%，生命科学32.73%，分析色谱13.78%，材料科学7.55%，实验耗材2.01%， 其他(补充)1.72%。 阿拉丁今年以来股价涨38.27%，近5个交易日涨1.16%，近20日涨5.88%，近60日涨25.28%。 分红方面，阿拉丁A股上市后累计派现2.41亿元。近三年，累计派现1.50亿元。 机构持仓方面，截止2025年3月31日，阿拉丁十大流通股东中，中欧医疗健康混合A（003095）位居第 三大流通股东，持股1357.71 ...

8月22日，恒达新材盘中下跌2.09%，截至10:59，报29.92元/股，成交2342.65万元，换手率1.68%，总市值26.77亿元。 截至3月31日，恒达新材股东户数7074.00，较上期减少11.18%；人均流通股6510股，较上期增加51.45%。2025年1月-3月，恒达新材实现营业收入2.42亿元，同比减少4.36%；归母净利润 分红方面，恒达新材A股上市后累计派现8075.57万元。 资金流向方面，主力资金净流出27.17万元，大单买入369.43万元，占比15.77%，卖出396.60万元，占比16.93%。 责任编辑：小浪快报 资料显示，浙江恒达新材料股份有限公司位于浙江省衢州市龙游县湖镇镇工业园区大明路8号，成立日期2002年5月22日，上市日期2023年8月22日，公司主营业务涉及专业从事特种纸原纸的研 恒达新材所属申万行业为：轻工制造-造纸-特种纸。所属概念板块包括：小盘、融资融券、增持回购、微盘股、医用耗材等。 恒达新材今年以来股价涨29.22%，近5个交易日涨0.03%，近20日涨6.86%，近60日涨15.57%。 ...

Group 1 - The core viewpoint of the news is that Hongda Co., Ltd. has shown significant stock price appreciation and positive financial performance in recent months [1][2] - As of August 22, Hongda's stock price increased by 43.96% year-to-date, with a 4.68% rise in the last five trading days and a 12.40% increase over the past 20 days [1] - The company reported a revenue of 8.22 billion yuan for the first quarter of 2025, reflecting a year-on-year growth of 15.04% [2] Group 2 - Hongda Co., Ltd. has a market capitalization of 289.78 billion yuan and a trading volume of 88.09 million yuan on August 22 [1] - The company is primarily engaged in mining and non-ferrous metal industries, with its main business involving phosphate fertilizers and related chemical products [1] - As of March 31, 2025, the number of shareholders increased to 60,900, with an average of 33,374 circulating shares per shareholder [2]

Group 1 - The core viewpoint of the article highlights the recent stock performance of Spring Medical, which has seen a year-to-date increase of 77.40%, but a decline of 4.84% over the last five trading days [2][3] - As of August 22, Spring Medical's stock price was reported at 22.62 yuan per share, with a market capitalization of 8.676 billion yuan [1] - The company primarily engages in the research, production, and sales of implantable orthopedic medical devices, with its main products including joint prosthetics and spinal implants [2] Group 2 - Spring Medical's revenue for the first quarter of 2025 reached 230 million yuan, reflecting a year-on-year growth of 3.60%, while the net profit attributable to shareholders was 58.071 million yuan, up 5.20% year-on-year [3] - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan distributed over the past three years [4] - As of March 31, 2025, the number of shareholders increased by 7.48% to 7,182, while the average circulating shares per person decreased by 6.99% to 11,063 shares [3]

资料显示，优刻得科技股份有限公司位于上海市杨浦区隆昌路619号10#B号楼201室，成立日期2012年3 月16日，上市日期2020年1月20日，公司主营业务涉及中立第三方云计算服务商,为客户打造一个安全、 可信赖的云计算服务平台。主营业务收入构成为：公有云50.63%，混合云35.41%，云通信8.26%，私有 云2.75%，解决方案及其他1.90%，边缘云1.05%。 资金流向方面，主力资金净流出65.15万元，特大单买入1946.72万元，占比5.05%，卖出1726.44万元， 占比4.48%；大单买入7661.03万元，占比19.87%，卖出7946.47万元，占比20.61%。 优刻得今年以来股价涨96.71%，近5个交易日涨4.44%，近20日涨4.25%，近60日涨35.53%。 今年以来优刻得已经8次登上龙虎榜，最近一次登上龙虎榜为2月14日，当日龙虎榜净买入1791.86万 元；买入总计3.37亿元 ，占总成交额比6.49%；卖出总计3.19亿元 ，占总成交额比6.15%。 8月22日，优刻得盘中上涨2.00%，截至09:42，报27.50元/股，成交3.86亿元，换手率3.51%，总市值 ...

今年以来江淮汽车已经1次登上龙虎榜，最近一次登上龙虎榜为6月3日，当日龙虎榜净买入-5.42亿元； 买入总计4.77亿元 ，占总成交额比9.90%；卖出总计10.19亿元 ，占总成交额比21.14%。 资料显示，安徽江淮汽车集团股份有限公司位于安徽省合肥市东流路176号，成立日期1999年9月30日， 上市日期2001年8月24日，公司主营业务涉及商用车、乘用车、汽车底盘及汽车核心零配件等的研发、 生产、销售与服务。主营业务收入构成为：商用车52.62%，乘用车29.07%，其他(补充)7.99%，客车 6.03%，其他3.94%，底盘0.35%。 江淮汽车所属申万行业为：汽车-商用车-商用载货车。所属概念板块包括：安徽国资、整车、国资改 革、增持回购、大盘等。 8月22日，江淮汽车盘中上涨2.10%，截至09:44，报50.14元/股，成交6.74亿元，换手率0.62%，总市值 1095.06亿元。 资金流向方面，主力资金净流入895.26万元，特大单买入7986.90万元，占比11.85%，卖出6049.30万 元，占比8.97%；大单买入1.26亿元，占比18.75%，卖出1.37亿元，占比20.30% ...

Group 1 - The core viewpoint of the news is that Spring Medical has shown significant stock performance, with an 88.85% increase in stock price year-to-date, despite a recent decline of 3.99% over the last five trading days [1] - As of August 19, the stock price of Spring Medical is 24.08 CNY per share, with a market capitalization of 9.236 billion CNY and a trading volume of 13.42 million CNY [1] - The company primarily engages in the research, production, and sales of orthopedic medical devices, focusing on joint prosthetics and spinal implants, with 99.92% of its revenue coming from medical device products [1][2] Group 2 - As of March 31, the company reported a revenue of 230 million CNY for Q1 2025, representing a year-on-year growth of 3.60%, and a net profit of 58.07 million CNY, which is a 5.20% increase compared to the previous year [2] - The company has distributed a total of 359 million CNY in dividends since its A-share listing, with 309 million CNY distributed over the past three years [3] - The number of shareholders increased by 7.48% to 7,182 as of March 31, while the average number of circulating shares per person decreased by 6.99% to 11,063 shares [2]

Company Overview - Junshi Biosciences has seen a stock price increase of 52.03% year-to-date, with a slight rise of 0.10% over the last five trading days, 6.10% over the last 20 days, and 38.04% over the last 60 days [2] - The company specializes in the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs, with 84.18% of its revenue coming from drug sales, 12.08% from technology licensing, and 3.73% from other sources [2] Financial Performance - For the period from January to March 2025, Junshi Biosciences reported revenue of 5.01 billion yuan, representing a year-on-year growth of 31.46%, while the net profit attributable to shareholders was -2.35 billion yuan, showing a year-on-year increase of 17.01% [2] Shareholder Information - As of March 31, 2025, the number of shareholders for Junshi Biosciences was 29,400, an increase of 0.24% from the previous period, with an average of 25,987 circulating shares per shareholder, a decrease of 0.23% [2] - The top ten circulating shareholders include notable ETFs, with 华夏上证科创板50成份ETF holding 30.25 million shares (a decrease of 5.05 million shares), and 易方达上证科创板50ETF holding 21.58 million shares (a decrease of 0.87 million shares) [3]

Group 1 - New Zhonggang's stock price reached a closing price of 8.54 yuan with a trading volume of 73.31 million yuan and a total market capitalization of 3.42 billion yuan on July 4 [1] - The stock appeared on the "Dragon and Tiger List" due to a price deviation of over 7%, with total buy and sell amounts of 36.62 million yuan and 7.46 million yuan respectively, resulting in a net buy of 29.16 million yuan [1] - The top five buying institutions included Kaiyuan Securities and Guotai Junan Securities, while Goldman Sachs and Haitong Securities were among the top sellers [1] Group 2 - Zhejiang New Zhonggang Thermal Power Co., Ltd. was established on October 17, 1997, and went public on July 7, 2021, focusing on the production and supply of thermal and electric power through cogeneration [2] - The company's revenue composition includes steam (71.77%), electricity (16.60%), compressed air (6.89%), coal (2.48%), energy storage electricity (2.03%), and others (0.16%) [2] - As of March 31, the number of shareholders increased by 3.87% to 21,300, while the average circulating shares per person decreased by 3.72% to 18,801 shares [2] Group 3 - New Zhonggang has distributed a total of 344 million yuan in dividends since its A-share listing, with 204 million yuan distributed over the past three years [3]